Key facts
- It has raised $22.0M; the latest was Later Stage VC ($22.0M) in Mar 2026.
- Notable investors include US National Science Foundation, Catcher Technology, Magnify.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Aneuvo
- ·The full record, as it builds
Funding rounds
No funding rounds for Aneuvo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aneuvo
Provider of emerging bioelectronic medicine intended for innovative disease and injury treatment. The company specializes in offering therapeutic devices for neuromodulation, spinal cord injury, neurorehabilitation, neurostimulation, and other diseases, enabling patients to get cured through traditional pharmaceutical approaches.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2016
- Employees
- 22
- Website
- aneuvo.com/
- Ownership
- Privately Held (backing)
Aneuvo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aneuvo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aneuvo in its N-PORT filings yet. We sweep new filings monthly.